Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer

Trial Profile

Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Everolimus (Primary) ; Levonorgestrel (Primary)
  • Indications Endometrial cancer; Hyperplasia
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Sep 2015 Planned primary completion date changed from 1 Aug 2026 to 1 Sep 2026, according to ClinicalTrials.gov record.
    • 24 Sep 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 03 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top